A weight-loss injection could soon be tested as a treatment for people facing the dangerous combination of alcohol dependence, obesity and chronic liver disease. Researchers in the United Kingdom are preparing a major clinical trial to determine whether semaglutide, widely known by the brand name Wegovy, can reduce alcohol consumption while also helping patients lose weight and improve liver health. The four-year project, called CURB—Controlling Unhealthy Relationships with Both alcohol and obesity—will investigate whether one medicine can address two closely connected drivers of liver damage. The study is being co-led by the University of Plymouth, University Hospitals Plymouth NHS Trust and the NIHR Biomedical Research Centre in Nottingham, with support from a £2.75 million grant through the National Institute for Health and Care Research Efficacy and Mechanism Evaluation programme.
The trial reflects a growing scientific interest in the wider effects of drugs originally developed for diabetes and obesity. Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists. These drugs imitate glucagon-like peptide-1, a hormone released by the gut after eating. GLP-1 acts on several systems involved in metabolism, including the pancreas, brain and digestive tract. It stimulates insulin release when blood glucose is elevated, reduces the release of glucagon, slows the movement of food through the stomach and increases sensations of fullness. Together, these effects can reduce food intake and support substantial weight loss. Researchers now want to discover whether the same biological pathways may influence alcohol-related urges and drinking behaviour in people with alcohol use disorder.
Alcohol dependence and obesity are individually important causes of liver disease, but their combination can be especially destructive. Excessive alcohol consumption can lead to the accumulation of fat in liver cells, inflammation, scarring and, in advanced cases, cirrhosis or liver failure. Obesity can also promote fatty liver disease through insulin resistance, altered fat metabolism and chronic low-grade inflammation. When the two conditions occur together, the resulting metabolic and inflammatory stress may accelerate the progression of liver injury. Around half of people living with alcohol-related liver disease are also obese, according to the researchers, creating a large patient population for whom existing treatment strategies often address only part of the problem.
Current care typically relies on a combination of alcohol-support services, psychological interventions, medical monitoring, nutritional advice and, in some cases, medicines designed to reduce alcohol cravings or prevent relapse. Weight management may be recommended separately, but patients with severe alcohol dependence and obesity can face substantial barriers to changing either behaviour. Alcohol can provide a concentrated source of calories, disrupt sleep and impair decision-making, while obesity-related metabolic changes may make weight loss more difficult. The CURB investigators believe that a treatment capable of influencing appetite, reward processing and metabolic regulation at the same time could offer a more integrated approach. However, whether semaglutide can meaningfully reduce alcohol use remains an open scientific question that must be tested in a controlled trial.
Preliminary laboratory and clinical observations have raised the possibility that GLP-1 signalling affects more than hunger. GLP-1 receptors are found in brain regions involved in reward, motivation and the response to substances such as alcohol. In experimental studies, altering this signalling has been associated with changes in alcohol-seeking and consumption, although findings from animals or small human studies cannot establish that semaglutide will work as a treatment for alcohol dependence. The drug may reduce drinking indirectly by lowering impulsive reward-seeking, or it may influence alcohol cravings through changes in appetite and the brain’s response to pleasurable stimuli. The CURB trial is designed to determine whether these proposed mechanisms translate into a clinically important reduction in alcohol intake.
Beginning in September 2026, the study is expected to recruit 268 adults from diverse backgrounds across England, Wales and Scotland. Participants will have alcohol dependence, obesity and chronic liver disease, allowing researchers to examine the treatment in the group most exposed to the combined risks. Volunteers will be randomly assigned to receive either semaglutide or a placebo, sometimes described as a dummy treatment, for 36 weeks. Neither participants nor the relevant members of the research team will know which treatment an individual receives during the blinded phase. This design is intended to separate the specific effects of semaglutide from changes that might occur because of medical attention, expectations or participation in a structured research programme.
The investigators will monitor several outcomes rather than focusing solely on body weight. A central question will be whether participants receiving semaglutide consume less alcohol than those receiving placebo. Researchers will also assess alcohol cravings, patterns of dependence, liver-related measures, body weight and indicators of metabolic health. Quality of life and overall wellbeing will be included because liver disease and addiction affect families, employment, mental health and daily functioning as well as laboratory results. The trial may also help identify whether any reduction in alcohol use is linked primarily to weight loss, to direct effects on craving, or to a combination of metabolic and neurological changes. Such information could be important for determining which patients are most likely to benefit.
The potential public-health impact is considerable. Alcohol is among the leading causes of death in the United Kingdom, and harmful drinking is described by the researchers as the country’s main cause of liver disease. Alcohol-related illness costs the National Health Service an estimated £5 billion each year, while the number of people living with obesity continues to increase. Liver disease is often diagnosed only after substantial damage has occurred, partly because early disease may produce few noticeable symptoms. Once advanced scarring develops, treatment options become limited and the risk of liver failure, cancer and premature death rises. If semaglutide were shown to lower alcohol consumption and improve metabolic health in this high-risk population, it could potentially slow disease progression before irreversible damage occurs. The study, however, will need to demonstrate that the benefits outweigh side effects, costs and the practical challenges of long-term treatment.
Semaglutide is not currently established as a treatment for alcohol dependence, and the new trial should not be interpreted as evidence that people should use weight-loss injections to control drinking without medical supervision. The medicine can cause gastrointestinal effects such as nausea, vomiting, diarrhoea and constipation, particularly during dose escalation, and clinicians must consider a patient’s wider medical history before prescribing it. Alcohol withdrawal can also be medically dangerous, potentially causing seizures, delirium or severe complications, and should not be attempted abruptly without appropriate professional support. The CURB study will therefore operate within specialist clinical services, with researchers monitoring participants’ safety while evaluating both benefits and adverse effects.
People with lived experience of alcohol dependence have helped shape the project and will continue to advise the research team throughout the trial. Their involvement is intended to make recruitment, treatment schedules and outcome measures more practical and inclusive, particularly for participants who may have previously found healthcare services difficult to access. Alongside the University of Plymouth and the Nottingham biomedical research centre, the collaboration includes the University of Nottingham, Loughborough University, the University of Exeter’s Exeter Clinical Trials Unit, the University of Leicester, Greater Manchester Mental Health NHS Foundation Trust, Nottingham University Hospitals NHS Trust and Imperial College London. Results from the controlled study could clarify whether a medicine originally designed to regulate blood sugar and appetite can also help interrupt the biological and behavioural cycle linking obesity, alcohol dependence and liver damage.
Subject of Research: Semaglutide as a potential treatment for alcohol dependence, obesity and chronic liver disease.
Article Title: Weight-Loss Drug Semaglutide to Be Tested Against Alcohol Cravings and Liver Damage
Keywords: Semaglutide, Wegovy, GLP-1, alcohol dependence, alcohol use disorder, obesity, chronic liver disease, alcohol-related liver disease, fatty liver disease, liver health, weight loss, clinical trial, CURB trial, addiction treatment, UK medical research, NIHR, University of Plymouth
Tags: alcohol consumption reduction strategiesdrug repurposing for liver diseaseeffects of gut hormones on metabolismGLP-1 receptor agonists for metabolic disordersimpact of diabetes medications on addictioninnovative approaches to liver disease treatmentobesity and alcohol dependence clinical trialsobesity management with injectable medicationspotential dual therapy for obesity and alcohol use disordersemaglutide liver health treatmentUK-based clinical research on weight-loss drugsweight-loss drugs for alcohol addiction
